LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis
Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms. The expression of HULC and miR-372-3p in osteosa...
Saved in:
Published in | Molecular medicine (Cambridge, Mass.) Vol. 26; no. 1; pp. 26 - 12 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central
18.03.2020
BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms.
The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay.
Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3'-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion.
Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment. |
---|---|
AbstractList | Abstract Background Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms. Methods The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay. Results Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3′-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion. Conclusion Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment. Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms.BACKGROUNDOsteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms.The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay.METHODSThe expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay.Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3'-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion.RESULTSOur results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3'-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion.Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment.CONCLUSIONOur study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment. Background Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms. Methods The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay. Results Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3′-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion. Conclusion Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment. Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of HULC in osteosarcoma, little is reported about its functional roles and molecular mechanisms. The expression of HULC and miR-372-3p in osteosarcoma tissues was quantified by qRT-PCR. The regulatory roles of HULC and miR-372-3p on cell proliferation, apoptosis, migration and invasion were determined by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays, respectively. The bioinformatics prediction software RAID v2.0 was used to predict the putative binding sites. The interactions among HULC, miR-372-3p and HMGB1 were explored by luciferase assay and western blot assay. Our results revealed elevated HULC and decreased miR-372-3p expression in both osteosarcoma tissues and cell lines. Overexpression of HULC or knockdown of miR-372-3p promoted osteosarcoma cell proliferation, migration and invasion and induced cell apoptosis. Bioinformatics and luciferase assays verified that HULC directly interacted with miR-372-3p to attenuate miR-372-3p binding to the HMGB1 3'-UTR. Furthermore, mechanistic investigations confirmed that activation of the miR-372-3p/HMGB1 regulatory loop by knockdown of miR-372-3p or overexpression of HMGB1 reversed the in vitro roles of HULC in promoting osteosarcoma cell proliferation, migration and invasion. Our study is the first to demonstrate that HULC may act as a ceRNA to modulate HMGB1 expression by competitively sponging miR-372-3p, leading to the regulation of osteosarcoma progression, which provides new insight into osteosarcoma diagnosis and treatment. |
ArticleNumber | 26 |
Author | Cen, Chao-Qun Li, Yong Liu, Jing-Jing Zhou, Jia-Hui Chen, Rui |
Author_xml | – sequence: 1 givenname: Yong surname: Li fullname: Li, Yong – sequence: 2 givenname: Jing-Jing surname: Liu fullname: Liu, Jing-Jing – sequence: 3 givenname: Jia-Hui surname: Zhou fullname: Zhou, Jia-Hui – sequence: 4 givenname: Rui surname: Chen fullname: Chen, Rui – sequence: 5 givenname: Chao-Qun surname: Cen fullname: Cen, Chao-Qun |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32188407$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kk1v1DAQhiNURD_gD3BAkbhwCfVHHMcXpHYF3UoLSBU9WxN7knqVxIudIPrvcXZbRHvgMLI17zOvRjNzmh2NfsQse0vJR0rr6jxSQhgp9kGoEIV4kZ1QweqCV6I-Sn8iqyIJ9Dg7jXGbaCpK8So75ozWdUnkSdZuRnPz7SJf325WuRvtbDDm0x3mu-C7gDE6P-a-zX2c0EcIxg-QN_d5wG7uYXJjt6cHd1NwyQq-O19_vbqkeXTdCH2_6PDbxdfZyxb6iG8e3rPs9svnH6t1sfl-db262BRGKDkVijWMgq2RKtVK2hphQclW8EZxk0RpOHC0KQsNSmKrCplAC6ZhjBFD-Fl2ffC1HrZ6F9wA4V57cHqf8KHTECZnetTUyBYZsZbIsgTkUCloeVuikU0FFpLXp4PXbm4GtAbHKUD_xPSpMro73flfWpKaCsWSwYcHg-B_zhgnPbhosO9hRD9HzbhUhKeVLOj7Z-jWzyFNMFGirBRXvJKJevdvR39beVxnAuoDYIKPMWCrjZvSlvzSoOs1JXq5HH24HL2P5XK0SKXsWemj-3-K_gDbOMXV |
CitedBy_id | crossref_primary_10_1016_j_omtn_2020_11_009 crossref_primary_10_3389_fcell_2022_773038 crossref_primary_10_3390_medicines7040019 crossref_primary_10_1016_j_compbiomed_2024_108403 crossref_primary_10_1016_j_biopha_2024_116924 crossref_primary_10_1093_carcin_bgac065 crossref_primary_10_1016_j_bbadis_2024_167357 crossref_primary_10_1111_cas_15989 crossref_primary_10_1038_s41598_020_80817_w crossref_primary_10_1515_biol_2021_0058 crossref_primary_10_1152_ajpcell_00296_2022 crossref_primary_10_15252_msb_20209810 crossref_primary_10_3727_096504020X15982623243955 crossref_primary_10_1016_j_cellsig_2023_110772 crossref_primary_10_1016_j_heliyon_2023_e15991 crossref_primary_10_3390_ijms24108993 crossref_primary_10_3390_cells11081267 crossref_primary_10_1186_s12929_024_01049_y crossref_primary_10_3389_fimmu_2022_1025532 crossref_primary_10_1155_2022_4342755 crossref_primary_10_1016_j_labinv_2022_100054 crossref_primary_10_3389_fgene_2022_1028477 crossref_primary_10_3389_fimmu_2021_763323 crossref_primary_10_3389_fgene_2022_1022155 crossref_primary_10_3390_ph15070811 |
Cites_doi | 10.1016/j.mam.2014.05.001 10.1016/j.cell.2005.06.036 10.1016/j.ejca.2012.10.018 10.1200/JCO.2014.59.4895 10.1038/bjc.2013.607 10.1038/nsmb0705-569 10.1161/CIRCRESAHA.117.311802 10.1038/s12276-018-0082-5 10.1016/j.bbagrm.2014.08.012 10.1093/emboj/cdg228 10.1196/annals.1294.016 10.1186/s12943-016-0530-6 10.1200/JCO.20.3.776 10.1080/14737140.2018.1413939 10.1016/S0092-8674(04)00045-5 10.2147/OTT.S149889 10.1016/j.ctrv.2013.11.006 10.3390/ijms17101712 10.1093/nar/gkq285 10.1007/s00018-016-2174-5 10.1111/jcmm.12956 10.1159/000479205 10.1002/cam4.1026 10.1517/17530050802608496 10.18632/oncotarget.4154 10.1186/1476-4598-13-92 10.3892/mmr.2014.2546 10.1158/0008-5472.CAN-11-2001 10.1155/2014/970607 10.4161/auto.8.2.18940 10.1016/j.cell.2011.07.014 10.1002/jcb.26273 10.1016/j.bbrc.2019.10.105 10.1146/annurev.cellbio.19.011102.111135 |
ContentType | Journal Article |
Copyright | 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. The Author(s) 2020 |
Copyright_xml | – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. – notice: The Author(s) 2020 |
DBID | AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s10020-020-00155-5 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1528-3658 |
EndPage | 12 |
ExternalDocumentID | oai_doaj_org_article_1c7fe20dd0744ae3a69af3f4ec7b6ada PMC7081592 32188407 10_1186_s10020_020_00155_5 |
Genre | Journal Article |
GeographicLocations | United States--US China Japan |
GeographicLocations_xml | – name: China – name: United States--US – name: Japan |
GroupedDBID | --- -ET 0R~ 123 29M 2WC 36B 5RE 5VS 7X7 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFO ACMJI ADBBV ADUKV AEGXH AENEX AFKRA AFPKN AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IH2 IHR ISR ITC KQ8 OK1 OVT P2P PHGZM PHGZT PIMPY RBZ RNS ROL RPM RSV SDH SJN SOJ SV3 TR2 UKHRP WOQ ACRMQ C24 M~E NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c597t-92b21ad8e199f71fc5da97f53b93c92b7c3a3ed5daabe70d66e25edacb2220c03 |
IEDL.DBID | 7X7 |
ISSN | 1076-1551 1528-3658 |
IngestDate | Wed Aug 27 01:30:35 EDT 2025 Thu Aug 21 14:21:38 EDT 2025 Fri Jul 11 04:39:39 EDT 2025 Mon Jun 30 13:41:16 EDT 2025 Thu Jan 02 22:58:17 EST 2025 Tue Jul 01 01:25:21 EDT 2025 Thu Apr 24 23:01:36 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | ceRNA HMGB1 Osteosarcoma HULC miR-372-3p |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c597t-92b21ad8e199f71fc5da97f53b93c92b7c3a3ed5daabe70d66e25edacb2220c03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/2546939367?pq-origsite=%requestingapplication% |
PMID | 32188407 |
PQID | 2546939367 |
PQPubID | 5066171 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_1c7fe20dd0744ae3a69af3f4ec7b6ada pubmedcentral_primary_oai_pubmedcentral_nih_gov_7081592 proquest_miscellaneous_2379031542 proquest_journals_2546939367 pubmed_primary_32188407 crossref_citationtrail_10_1186_s10020_020_00155_5 crossref_primary_10_1186_s10020_020_00155_5 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-03-18 |
PublicationDateYYYYMMDD | 2020-03-18 |
PublicationDate_xml | – month: 03 year: 2020 text: 2020-03-18 day: 18 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: New York – name: London |
PublicationTitle | Molecular medicine (Cambridge, Mass.) |
PublicationTitleAlternate | Mol Med |
PublicationYear | 2020 |
Publisher | BioMed Central BMC |
Publisher_xml | – name: BioMed Central – name: BMC |
References | MJ Wheelock (155_CR32) 2003; 19 Y Wang (155_CR31) 2018; 50 DJ Harrison (155_CR10) 2018; 18 Z Li (155_CR20) 2017; 42 RB Hazan (155_CR11) 2004; 1014 155_CR14 155_CR36 Y Wang (155_CR30) 2017; 10 J Huang (155_CR13) 2012; 72 155_CR22 J Wang (155_CR28) 2010; 38 A Luetke (155_CR23) 2014; 40 D Kong (155_CR18) 2018; 119 J Huang (155_CR12) 2012; 8 C Catalanotto (155_CR6) 2016; 17 T Sallam (155_CR24) 2018; 122 SS Bielack (155_CR5) 2002; 20 R Kang (155_CR15) 2014; 40 G Christofori (155_CR7) 2003; 22 T Kinoshita (155_CR16) 2013; 109 N Bartonicek (155_CR4) 2016; 15 SU Schmitz (155_CR26) 2016; 73 CM Croce (155_CR8) 2005; 122 155_CR9 Guodong Yang (155_CR35) 2014; 1839 SY Xu (155_CR34) 2018; 22 Q Wang (155_CR29) 2017; 6 DAJIANG WU (155_CR33) 2014; 10 DP Bartel (155_CR3) 2004; 116 155_CR27 AM Ardekani (155_CR1) 2010; 2 L Salmena (155_CR25) 2011; 146 B Bartel (155_CR2) 2005; 12 W-C Liang (155_CR21) 2015; 6 C Kong (155_CR17) 2009; 3 HE Lee (155_CR19) 2013; 49 |
References_xml | – volume: 40 start-page: 1 year: 2014 ident: 155_CR15 publication-title: Mol Asp Med doi: 10.1016/j.mam.2014.05.001 – volume: 122 start-page: 6 issue: 1 year: 2005 ident: 155_CR8 publication-title: Cell doi: 10.1016/j.cell.2005.06.036 – volume: 49 start-page: 1448 issue: 6 year: 2013 ident: 155_CR19 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.10.018 – ident: 155_CR14 doi: 10.1200/JCO.2014.59.4895 – volume: 109 start-page: 2636 issue: 10 year: 2013 ident: 155_CR16 publication-title: Br J Cancer doi: 10.1038/bjc.2013.607 – volume: 12 start-page: 569 issue: 7 year: 2005 ident: 155_CR2 publication-title: Nat Struct Mol Biol doi: 10.1038/nsmb0705-569 – volume: 122 start-page: 155 issue: 1 year: 2018 ident: 155_CR24 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.117.311802 – volume: 50 start-page: 57 issue: 5 year: 2018 ident: 155_CR31 publication-title: Exp Mol Med doi: 10.1038/s12276-018-0082-5 – volume: 1839 start-page: 1097 issue: 11 year: 2014 ident: 155_CR35 publication-title: Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms doi: 10.1016/j.bbagrm.2014.08.012 – volume: 22 start-page: 2318 issue: 10 year: 2003 ident: 155_CR7 publication-title: EMBO J doi: 10.1093/emboj/cdg228 – volume: 1014 start-page: 155 year: 2004 ident: 155_CR11 publication-title: Ann N Y Acad Sci doi: 10.1196/annals.1294.016 – volume: 15 start-page: 43 issue: 1 year: 2016 ident: 155_CR4 publication-title: Mol Cancer doi: 10.1186/s12943-016-0530-6 – volume: 20 start-page: 776 issue: 3 year: 2002 ident: 155_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.20.3.776 – volume: 18 start-page: 39 issue: 1 year: 2018 ident: 155_CR10 publication-title: Expert Rev Anticancer Ther doi: 10.1080/14737140.2018.1413939 – volume: 116 start-page: 281 issue: 2 year: 2004 ident: 155_CR3 publication-title: Cell doi: 10.1016/S0092-8674(04)00045-5 – volume: 10 start-page: 5355 year: 2017 ident: 155_CR30 publication-title: Oncotargets Ther doi: 10.2147/OTT.S149889 – volume: 22 start-page: 62 issue: 1 year: 2018 ident: 155_CR34 publication-title: Eur Rev Med Pharmacol Sci – volume: 40 start-page: 523 issue: 4 year: 2014 ident: 155_CR23 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2013.11.006 – volume: 17 start-page: 1712 issue: 10 year: 2016 ident: 155_CR6 publication-title: Int J Mol Sci doi: 10.3390/ijms17101712 – volume: 38 start-page: 5366 issue: 16 year: 2010 ident: 155_CR28 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkq285 – volume: 73 start-page: 2491 issue: 13 year: 2016 ident: 155_CR26 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-016-2174-5 – ident: 155_CR36 doi: 10.1111/jcmm.12956 – volume: 42 start-page: 1407 year: 2017 ident: 155_CR20 publication-title: Cell Physiol Biochem doi: 10.1159/000479205 – volume: 6 start-page: 1323 issue: 6 year: 2017 ident: 155_CR29 publication-title: Cancer Med doi: 10.1002/cam4.1026 – volume: 3 start-page: 13 issue: 1 year: 2009 ident: 155_CR17 publication-title: Expert Opin Med Diagn doi: 10.1517/17530050802608496 – volume: 6 start-page: 22513 issue: 26 year: 2015 ident: 155_CR21 publication-title: Oncotarget doi: 10.18632/oncotarget.4154 – ident: 155_CR22 doi: 10.1186/1476-4598-13-92 – volume: 10 start-page: 2415 issue: 5 year: 2014 ident: 155_CR33 publication-title: Molecular Medicine Reports doi: 10.3892/mmr.2014.2546 – volume: 72 start-page: 230 issue: 1 year: 2012 ident: 155_CR13 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-2001 – ident: 155_CR27 doi: 10.1155/2014/970607 – volume: 8 start-page: 275 issue: 2 year: 2012 ident: 155_CR12 publication-title: Autophagy doi: 10.4161/auto.8.2.18940 – volume: 146 start-page: 353 issue: 3 year: 2011 ident: 155_CR25 publication-title: Cell doi: 10.1016/j.cell.2011.07.014 – volume: 119 start-page: 1050 issue: 1 year: 2018 ident: 155_CR18 publication-title: J Cell Biochem doi: 10.1002/jcb.26273 – ident: 155_CR9 doi: 10.1016/j.bbrc.2019.10.105 – volume: 2 start-page: 161 issue: 4 year: 2010 ident: 155_CR1 publication-title: Avicenna J Med Biotechnol – volume: 19 start-page: 207 year: 2003 ident: 155_CR32 publication-title: Annu Rev Cell Dev Biol doi: 10.1146/annurev.cellbio.19.011102.111135 |
SSID | ssj0021545 |
Score | 2.427635 |
Snippet | Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the importance of... Background Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated the... Abstract Background Osteosarcoma is a malignancy that normally affects children, adolescents, and young adults. Although accumulating evidence has demonstrated... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 26 |
SubjectTerms | Apoptosis Bone cancer Cell cycle Cell growth ceRNA Epigenetics Gene expression HMGB1 HULC Liver cancer Metastasis MicroRNAs miR-372-3p Osteosarcoma Proteins Sarcoma Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SEHwRvz2tEsE3Cd0km2Tz2BbrIW0figd9WyZfeGB3S-8K9r93kuwdPRF98WFfkglkM5Od37AzvyHkoxSNDZwn5kSUrJUGmLWgGHpuDtp1nRW5dvjsXM8X7ddLdXmv1VfOCav0wPXgDrg3KYomBPR1LUQJ2kKSqY3eOA2hQCP0eZtgagq1MjCo2YaaZVCwKZfpdC6ayyFTeTJgYGrHJRXm_j_Bzd-zJu-5oZMn5PGEH-lh3fdT8iAOz8jD2lHy7jlJp4O_OD-k88XpMcVwGxW3oojxaMnDqhwcdEw0l3aMKzTy8Qqou6M3tSU9-rEifbW8wG-CYPL6YH725YjTnOYBhb6bws_l6gVZnHz-djxnUysF5jFiWDMrnOAQusitTYYnrwJYk5R0VnqcNF6CjAFHwUXTBK2jUDGAd4gfGt_Il2RvGIf4mlDg0SYVBcgmthjcgUyRt5BJZhSooGaEb06z9xPPeG538aMv8Uan-6qBvjxZAz2u-bRdc11ZNv4qfZSVtJXMDNllAO2mn-ym_5fdzMj-RsX9dG1XfW4OYKWV2szIh-00Xrj8FwWGON6ijDQ2t8ZoxYy8qhax3YlEwIQRM642O7ays9XdmWH5vZB6G8Rmyoo3_-Pd3pJHoti3ZLzbJ3vrm9v4DrHT2r0v1-QXuyUU_Q priority: 102 providerName: Directory of Open Access Journals |
Title | LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32188407 https://www.proquest.com/docview/2546939367 https://www.proquest.com/docview/2379031542 https://pubmed.ncbi.nlm.nih.gov/PMC7081592 https://doaj.org/article/1c7fe20dd0744ae3a69af3f4ec7b6ada |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LaxsxEBZtQqGX0nfdpkaF3orISlqtVqcShySmJKaYGnxbZvVoDc2uazvQ_PuOtGunLiUH7UEPEDsj6Rtp5htCPkqRGcd5YLXwkuVSAzMGFMOTm0NRl6URMXb4alKMZ_mXuZr3F27r3q1yuyemjdq1Nt6RH0fediONLPTn5S8Ws0bF19U-hcZDchipy6JLl57fGVwRHnQ-hwWL0GAbNFMWMXQuGk6pRNjA1N7BlPj7_wc6__Wd_OswOn9KnvQokp50Yn9GHvjmOXnU5ZW8fUHCZWOnkxM6nl2eUjS6UXxrikiPJm-sjomDtoHGAI92jareXgOtb-mqS0yPp1nqfb2Y4s4gmFwej68uRpxGZw9IJN4Ufi_WL8ns_Ozb6Zj1CRWYRbthw4yoBQdXem5M0DxY5cDooGRtpMVGbSVI77AWaq8zVxReKO_A1ogiMpvJV-SgaRv_hlDg3gTlBcjM52jigQye5xCpZhQopwaEb_9mZXu28Zj04meVrI6yqDoJVKlECVQ45tNuzLLj2ri39ygKadcz8mSninb1veqXXcWtDl5kziFSysFLKAwEGXJvdV2AgwE52oq46hfvurpTtQH5sGvGZRffUqDx7Q32kdrEBBm5GJDXnUbsZiIRNqHdjKP1nq7sTXW_pVn8SNTeGhGaMuLt_dN6Rx6LpLmS8fKIHGxWN_49YqNNPUwLYEgOR2eTr9NhumHA78Wc_wG_nQ4y |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLdGJwQXxDeFAUaCE7IW20kcHxBax0bH2gpVq7RbcPxRKrGktJ2g_xR_I89OUihCu-3gi_0cWX7v2b8Xvw-EXnMWSUOpIwWznMRcKCKlSgjc3FSlRZZJ5mOHh6O0P4k_nSfnO-hXGwvj3SrbMzEc1KbS_h_5vs_bLrnkqXg__0581Sj_utqW0KjF4tSuf4DJtnx38gH4-4ax46Ozwz5pqgoQDeB5RSQrGFUms1RKJ6jTiVFSuIQXkmsYFJorbg30qsKKyKSpZYk1ShdwlUY64vDdG2g35mDKdNBu72j0ebwx8Twgqb0cU-LBSBumk6U-WM-baqF5oEKSraswVAz4H8z911vzr-vv-C660-BWfFAL2j20Y8v76GZdyXL9ALlBqcejA9yfDA4xmPkgMEsM2BIH_6869weuHPYhJdUSdrG6ULhY44Wdhvph5TRQX8zGcBYxwuf7_eHHHsXevUSFtOFY_ZwtH6LJtWz2I9Qpq9I-QVhRK11imeKRjcGoVNxZGiuf3CZRiUm6iLa7mesmv7kvs_EtD3ZOluY1B_LQPAdymPN2M2deZ_e4krrnmbSh9Jm5Q0e1mOaNoudUC2dZZAxgs1hZrlKpHHex1aJIlVFdtNeyOG-Oi2X-R7i76NVmGBTdv96o0laXQMOF9CU5YtZFj2uJ2KyEA1ADSx1miy1Z2Vrq9kg5-xqSiQvAhIlkT69e1kt0q382HOSDk9HpM3SbBSnmhGZ7qLNaXNrngMxWxYtGHTD6ct0a-Btzo0rx |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFLfGEIgL4pvCACPBCVmN7TiODwjtg9KxrkITlXrLnNgulbakaztB_zX-Op6dpKMI7baDL_ZzZPm9Z_9e_D4QesdZpAyljuTMchJzqYlSWhC4ualO8jRVzMcOHw-T_ij-OhbjLfS7jYXxbpXtmRgOalMV_h951-dtV1zxRHZd4xbx7aD3aXZBfAUp_9LaltOoReTIrn6C-bb4eHgAvH7PWO_z9_0-aSoMkAKA9JIoljOqTWqpUk5SVwijlXSC54oXMCgLrrk10KtzKyOTJJYJa3SRw7UaFRGH795CtyUX1OuYHF8Zex6a1P6OCfGwpA3YSRMftueNttA8ZCFi41IMtQP-B3j_9dv86yLsPUD3GwSLd2uRe4i2bPkI3alrWq4eIzcoi5PhLu6PBvsYDH4QnQUGlImDJ1idBQRXDvvgkmoBe1ida5yv8NxOQiWxchKoz6cncCoxwmfd_vGXPYq9o4kOCcSx_jVdPEGjG9nqp2i7rEr7HGFNrXLCMs0jG4N5qbmzNNY-zY3QwogOou1uZkWT6dwX3DjLgsWTJlnNgSw0z4EM5nxYz5nVeT6upd7zTFpT-hzdoaOaT7JG5TNaSGdZZAygtFhbrhOlHXexLWSeaKM7aKdlcdYcHIvsSsw76O16GFTev-Po0laXQMOl8sU5YtZBz2qJWK-EA2QDmx1myw1Z2Vjq5kg5_RHSiktAh0KxF9cv6w26C3qXDQ6HRy_RPRaEmBOa7qDt5fzSvgKItsxfB13A6PSmle8PMa1NwQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LncRNA+HULC+induces+the+progression+of+osteosarcoma+by+regulating+the+miR-372-3p%2FHMGB1+signalling+axis&rft.jtitle=Molecular+medicine+%28Cambridge%2C+Mass.%29&rft.au=Li%2C+Yong&rft.au=Liu%2C+Jing-Jing&rft.au=Zhou%2C+Jia-Hui&rft.au=Chen%2C+Rui&rft.date=2020-03-18&rft.issn=1076-1551&rft.eissn=1528-3658&rft.volume=26&rft.issue=1&rft_id=info:doi/10.1186%2Fs10020-020-00155-5&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s10020_020_00155_5 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1076-1551&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1076-1551&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1076-1551&client=summon |